Online citations, reference lists, and bibliographies.

Successful Use Of Recombinant Factor VIIa (NovoSeven) During Cardiac Surgery In A Pediatric Patient With Glanzmann Thrombasthenia

B.T. Yilmaz, B. Alioglu, E. Ozyurek, H.T. Akay, S. Mercan, N. Ozbek
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Glanzmann thrombasthenia is a rare, hereditary, congenital disorder of platelet function characterized by inappropriate bleeding that is difficult to control. Recombinant activated factor VII (rFVIIa) is a new treatment that is used to stop bleeding and provide surgical support for these patients. This report describes the use of rFVIIa to prevent serious bleeding during and after open-heart surgery in a child with Glanzmann thrombasthenia.
This paper references
A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa.
L. Tengborn (1996)
Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group.
A. Goodeve (2000)
Qualitative disorders of platelet function
SP Levine (1999)
The effect of steroid and intravenous immunoglobulin on thrombopoietin levels in pediatric patients with immune thrombocytopenic purpura.
U. Koçak (2000)
Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding.
M. Smith (2001)
Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery
M. Al Douri (2000)
Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.
A. Shapiro (1998)
Heart transplant in a factor VIII‐deficient patient with a high‐titre inhibitor: perioperative management using high‐dose continuous infusion factor VIII and recombinant factor VIIa
S. Sheth (2001)
Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures.
R. D'Oiron (2000)
Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group.
S. Schulman (1998)
New alternatives for control of severe cardiac surgical bleeding
R. Gill (2004)
Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000.
U. Hedner (2000)
Gender difference in factor VII and in activated factor VII levels in unstable angina.
H. Benamer (1996)
Thalidomide and low‐dose dexamethasone in myeloma treatment
B. Myers (2001)
Use of recombinant factor VIIa for post‐operative haemorrhage in a patient with Glanzmann's thrombasthenia and human leucocyte antigen antibodies
R. Patel (2001)
Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
E. Santagostino (2001)
Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia.
M. Poon (1999)
Safety, efficacy and lessons from continuous infusion with rFVIIa
C. Lee (1998)

This paper is referenced by
CHAPTER 68 – Factor VIIa
M. Poon (2007)
A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery.
G. Despotis (2008)
Perioperative Management of a Patient with Glanzmann's Thrombasthenia for Mitral Valve Repair Under Cardiopulmonary Bypass
Parimala Prasanna Simha (2017)
Recombinant activated factor VII and epsilon aminocaproic acid treatment of a patient with Glanzmann's thrombasthenia for nasal polipectomy
B. Gunaydin (2006)
[Bleeding after cardiac surgery: the role of recombinant factor VIIa].
C. von Heymann (2006)
Scientific Statement From the American Heart Association Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease: A
C. Webb (2014)
Defining the role of recombinant activated factor VII in pediatric cardiac surgery: Where should we go from here?*
O. Warren (2009)
Effects of cardiac surgery on hemostasis.
M. Hartmann (2006)
Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann’s thrombasthenia
M. Poon (2007)
Open aortic valve replacement in a patient with Glanzmann's thrombasthenia: a multidisciplinary strategy to minimize perioperative bleeding.
A. Sheikh (2014)
Fatal Thrombosis After Factor VII Administration During Extracorporeal Membrane Oxygenation.
M. Swaminathan (2008)
On the Dose of Succinylcholine Required for Excellent Intubating Conditions
M. T. V. Chan (2006)
Review of the Off-Label Use of Recombinant Activated Factor VII in Pediatric Cardiac Surgery Patients
N. Guzzetta (2012)
Risks associated with bleeding and transfusion: rationale for the optimal management of bleeding after cardiac surgery
G. Despotis (2007)
Blutungen nach herzchirurgischen Operationen - Die Rolle des rekombinanten Faktors VIIa
C. Heymann (2006)
NovoSeven (recombinant factor VIIa) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann’s thrombasthenia
M. Franchini (2014)
Chapter 61 – Factor VIIa
Poon Man-Chiu (2013)
Should studies on Glanzmann thrombasthenia not be telling us more about cardiovascular disease and other major illnesses?
A. Nurden (2017)
Recombinant activated factor VII in cardiac surgery
M. Ranucci (2007)
Perioperative haemostatic management of Glanzmann thrombasthenia for abdominal surgery
S. Lison (2009)
Recombinant factor VIIa: a universal haemostatic agent?
R. Gill (2006)
Evaluation of Off-Label Recombinant Activated Factor VII for Multiple Indications in Children
P. Reiter (2007)
The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders.
M. Poon (2007)
Successful Use of Recombinant Factor VIIa (NovoSeven®) During Cardiac Surgery in a Pediatric Patient with Congenital Factor XI Deficiency
Z. Avci (2007)
Tricuspid valve replacement and ventricular septal defect repair in a patient with Glanzmann thrombasthenia.
Jake Gillen (2010)
Unlabeled uses of factor VIIa (recombinant) in pediatric patients.
Irene S Hong (2010)
Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association.
T. Giglia (2013)
Successful Use of Recombinant Factor VIIa (NovoSeven) in Children With Compartment Syndrome: Two Case Reports
B. Alioglu (2006)
Coronary artery disease in women: a review on prevention, pathophysiology, diagnosis, and
Leila Fernandes Araújo (2006)
Perioperative Hemostatic Management of a Pediatric Patient with Glanzmann Thrombasthenia Undergoing Osteoplastic Craniotomy and Hematoma Removal: A Case Report
S. Lee (2019)
Transcatheter aortic valve implantation in a person with haemophilia
B. Merron (2015)
Massive transfusion and blood product use in the pediatric trauma patient.
Jeffrey J. Dehmer (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar